Pretransplant IgG Subclasses of Donor-Specific Human Leukocyte Antigen Antibodies and Development of Antibody-Mediated Rejection

被引:81
作者
Hoenger, Gideon [1 ]
Hopfer, Helmut [2 ]
Arnold, Marie-Luise [3 ]
Spriewald, Bernd M. [3 ]
Schaub, Stefan [1 ]
Amico, Patrizia [1 ]
机构
[1] Univ Basel Hosp, Clin Transplantat Immunol & Nephrol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
[3] Univ Erlangen Nurnberg, Dept Internal Med 3, Inst Clin Immunol, D-8520 Erlangen, Germany
基金
瑞士国家科学基金会;
关键词
HLA antibodies; IgG subclasses; Complement activation; Antibody-mediated rejection; Renal transplantation; IMMUNOGLOBULIN-G; KIDNEY-TRANSPLANTS; CLINICAL-RELEVANCE; HLA; RISK;
D O I
10.1097/TP.0b013e31821cdf0d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The subclass of IgG antibodies contributes to their capability to activate complement. It is currently unknown whether the pretransplant IgG subclass composition allows distinguishing harmful from presumably irrelevant donor-specific human leukocyte antigen (HLA) antibodies (HLA-DSA) detected by single-antigen flow beads (SAFB). Methods. Seventy-four patients transplanted in the presence of HLA-DSA were investigated. HLA-DSA characteristics were not different between patients experiencing antibody-mediated rejection (AMR) (n = 40) and patients who did not (n = 34) experience AMR. Sera were reanalyzed using SAFB with IgG subclass-specific reporter antibodies. Results. The 74 patients had in total 141 HLA-DSA. IgG(1) was the predominant subclass (78%), followed by IgG(2) (49%), IgG(3) (36%), and IgG(4) (20%). When grouped according to the complement-activating capability, only 4 of 74 patients (5%) had exclusively weak/no complement-activating HLA-DSA (i.e., IgG(2) and IgG(4)), 21 of 74 patients (28%) had isolated strong complement-activating HLA-DSA (i.e., IgG(1) and IgG(3)), and 46 of 74 patients (62%) had a mixture of both. There was no difference between the strong complement-activating and the mixture group regarding incidence of AMR (57% vs. 54%; P=0.81), phenotypes of AMR (P=0.70), and death-censored allograft survival at 5 years (78% vs. 78%; P=0.74). Interestingly, patients with exclusively weak/no complement-activating HLA-DSA (n=4) had a numerically lower incidence of AMR (25%) and no allograft loss has occurred yet. Conclusion. In 90% of patients, pretransplant HLA-DSA are composed of isolated strong or a mixture of strong and weak/no complement-activating IgG subclasses. Because outcomes in these two groups were similar, pretransplant IgG subclass analysis is likely not providing substantial value beyond the standard IgG SAFB assay for pretransplant risk stratification.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 21 条
[1]   Clinical Relevance of Pretransplant Donor-Specific HLA Antibodies Detected by Single-Antigen Flow-Beads [J].
Amico, Patrizia ;
Hoenger, Gideon ;
Mayr, Michael ;
Steiger, Juerg ;
Hopfer, Helmut ;
Schaub, Stefan .
TRANSPLANTATION, 2009, 87 (11) :1681-1688
[2]   Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates [J].
Arnold, M. -L. ;
Dechant, M. ;
Doxiadis, I. I. N. ;
Spriewald, B. M. .
TISSUE ANTIGENS, 2008, 72 (01) :60-66
[3]   Detection and specification of noncomplement binding anti-HLA alloantibodies [J].
Arnold, ML ;
Zacher, T ;
Dechant, M ;
Kalden, JR ;
Doxiadis, IIN ;
Spriewald, BM .
HUMAN IMMUNOLOGY, 2004, 65 (11) :1288-1296
[4]   Efficacy of Induction Therapy with ATG and Intravenous Immunoglobulins in Patients with Low-Level Donor-Specific HLA-Antibodies [J].
Baechler, K. ;
Amico, P. ;
Hoenger, G. ;
Bielmann, D. ;
Hopfer, H. ;
Mihatsch, M. J. ;
Steiger, J. ;
Schaub, S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) :1254-1262
[5]   Determinants of the complement-fixing ability of recipient presensitization against HLA antigens [J].
Bartel, Gregor ;
Wahrmann, Markus ;
Exner, Markus ;
Regele, Heinz ;
Schillinger, Martin ;
Hoerl, Walter H. ;
Boehmig, Georg A. .
TRANSPLANTATION, 2007, 83 (06) :727-733
[6]   Alloantibody Levels and Acute Humoral Rejection Early After Positive Crossmatch Kidney Transplantation [J].
Bums, J. M. ;
Comell, L. D. ;
Perry, D. K. ;
Pollinger, H. S. ;
Gloor, J. M. ;
Kremers, W. K. ;
Gandhi, M. J. ;
Dean, P. G. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (12) :2684-2694
[7]   CAPILLARY DEPOSITION OF C4D COMPLEMENT FRAGMENT AND EARLY RENAL GRAFT LOSS [J].
FEUCHT, HE ;
SCHNEEBERGER, H ;
HILLEBRAND, G ;
BURKHARDT, K ;
WEISS, M ;
RIETHMULLER, G ;
LAND, W ;
ALBERT, E .
KIDNEY INTERNATIONAL, 1993, 43 (06) :1333-1338
[8]   Immunoglobulin-G subclass antidonor reactivity in transplant recipients [J].
Gao, ZH ;
McAlister, VC ;
Wright, JR ;
McAlister, CC ;
Peltekian, K ;
MacDonald, AS .
LIVER TRANSPLANTATION, 2004, 10 (08) :1055-1059
[9]   Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival [J].
Griffiths, EJ ;
Nelson, RE ;
Dupont, PJ ;
Warrens, AN .
TRANSPLANTATION, 2004, 77 (11) :1771-1773
[10]   Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? [J].
Gupta, Arun ;
Iveson, Victoria ;
Varagunam, Mira ;
Bodger, Stephen ;
Sinnott, Paul ;
Thuraisingham, Raj C. .
TRANSPLANTATION, 2008, 85 (08) :1200-1204